{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T07:20:12Z","timestamp":1792653612364,"version":"4.5.0"},"reference-count":125,"publisher":"Bentham Science Publishers Ltd.","issue":"40","funder":[{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Project of China","doi-asserted-by":"publisher","award":["2018YFC1106103"],"award-info":[{"award-number":["2018YFC1106103"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CMC"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:sec>\n<jats:title>:<\/jats:title>\n<jats:p>Retinal degenerative diseases are the main retinal diseases that threaten vision.\nMost retinal degenerative diseases are inherited diseases, including autosomal recessive\ninheritance, autosomal dominant inheritance, X-linked inheritance, and mitochondrial inheritance;\ntherefore, emerging gene therapy strategies may provide an alternative method\nof treatment. Currently, three viral vectors are usually used in gene therapy studies: adenovirus,\nlentivirus, and adeno-associated virus. Other gene therapies have their own advantages,\nsuch as DNA nanoparticles, antisense oligonucleotides, and gene editing therapies.\nIn addition, retinal degenerative diseases are often accompanied by abnormalities of retinal\ncells, including photoreceptor and retinal pigment epithelial cells. At present, stem\ncell transplantation is a promising new treatment for retinal degenerative diseases. Common\nsources of stem cells include retinal progenitor cells, induced pluripotent stem cells,\nembryonic stem cells, and mesenchymal stem cells. In addition, retina explant cultures in\nvitro can be used as an effective platform for screening new therapies for retinal degenerative\ndiseases. Drugs that actually reach the retinal layer are more controlled, more consistent,\nand less invasive when using retinal explants. Furthermore, studies have shown\nthat the imbalance of the gut microbiota is closely related to the occurrence and development\nof diabetic retinopathy. Therefore, the progression of diabetic retinopathy may be\nrestrained by adjusting the imbalance of the gut microbiota. The purpose of this review is\nto discuss and summarize the molecular mechanisms and potential therapeutic strategies\nof retinal degenerative diseases.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/0929867328666211129122908","type":"journal-article","created":{"date-parts":[[2021,11,30]],"date-time":"2021-11-30T04:35:55Z","timestamp":1638246955000},"page":"6125-6140","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Retinal Degeneration: Molecular Mechanisms and Therapeutic Strategies"],"prefix":"10.2174","volume":"29","author":[{"given":"Xue","family":"Wu","sequence":"first","affiliation":[{"name":"Department of Ophthalmology, West China Hospital, Sichuan University, Chengdu 610041, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naihong","family":"Yan","sequence":"additional","affiliation":[{"name":"Research Laboratory of Ophthalmology, West China Hospital, Sichuan University, Chengdu 610041,\nChina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, West China Hospital, Sichuan University, Chengdu 610041, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1159\/000497296","volume":"206","author":"Rettinger C.L.","year":"2018","unstructured":"Rettinger C.L.; Wang H.C.; Current advancements in the development and characterization of full-thickness adult neuroretina organotypic culture systems. Cells Tissues Organs 2018,206(3),119-132","journal-title":"Cells Tissues Organs"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1242\/dmm.017913","volume":"8","author":"Veleri S.","year":"2015","unstructured":"Veleri S.; Lazar C.H.; Chang B.; Sieving P.A.; Banin E.; Swaroop A.; Biology and therapy of inherited retinal degenerative disease: Insights from mouse models. Dis Model Mech 2015,8(2),109-129","journal-title":"Dis Model Mech"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"617377","DOI":"10.3389\/fnins.2020.617377","volume":"14","author":"Lin Y.","year":"2021","unstructured":"Lin Y.; Ren X.; Chen Y.; Chen D.; Interaction between mesenchymal stem cells and retinal degenerative microenvironment. Front Neurosci 2021,14,617377","journal-title":"Front Neurosci"},{"key":"ref=4","first-page":"1985","volume":"19","author":"Gorbatyuk M.","year":"2013","unstructured":"Gorbatyuk M.; Gorbatyuk O.; Review: Retinal degeneration: Focus on the unfolded protein response. Mol Vis 2013,19,1985-1998","journal-title":"Mol Vis"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/j.scr.2015.02.003","volume":"14","author":"Mead B.","year":"2015","unstructured":"Mead B.; Berry M.; Logan A.; Scott R.A.; Leadbeater W.; Scheven B.A.; Stem cell treatment of degenerative eye disease. Stem Cell Res (Amst) 2015,14(3),243-257","journal-title":"Stem Cell Res (Amst)"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1046\/j.1525-1594.2003.07304.x","volume":"27","author":"Margalit E.","year":"2003","unstructured":"Margalit E.; Sadda S.R.; Retinal and optic nerve diseases. Artif Organs 2003,27(11),963-974","journal-title":"Artif Organs"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"1901","DOI":"10.1001\/jama.2014.3192","volume":"311","author":"Weinreb R.N.","year":"2014","unstructured":"Weinreb R.N.; Aung T.; Medeiros F.A.; The pathophysiology and treatment of glaucoma: A review. JAMA 2014,311(18),1901-1911","journal-title":"JAMA"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"93751","DOI":"10.1172\/jci.insight.93751","volume":"2","author":"Duh E.J.","year":"2017","unstructured":"Duh E.J.; Sun J.K.; Stitt A.W.; Diabetic retinopathy: Current understanding, mechanisms, and treatment strategies. JCI Insight 2017,2(14),93751","journal-title":"JCI Insight"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1152\/physrev.00021.2004","volume":"85","author":"Strauss O.","year":"2005","unstructured":"Strauss O.; The retinal pigment epithelium in visual function. Physiol Rev 2005,85(3),845-881","journal-title":"Physiol Rev"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.neuron.2012.06.018","volume":"75","author":"Ambati J.","year":"2012","unstructured":"Ambati J.; Fowler B.J.; Mechanisms of age-related macular degeneration. Neuron 2012,75(1),26-39","journal-title":"Neuron"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"8374647","DOI":"10.1155\/2018\/8374647","volume":"2018","author":"Hern\u00e1ndez-Zimbr\u00f3n L.F.","year":"2018","unstructured":"Hern\u00e1ndez-Zimbr\u00f3n L.F.; Zamora-Alvarado R.; Ochoa-De la Paz L.; Velez-Montoya R.; Zenteno E.; Gulias-Ca\u00f1izo R.; Quiroz-Mercado H.; Gonzalez-Salinas R.; Age-related macular degeneration: New paradigms for treatment and management of AMD. Oxid Med Cell Longev 2018,2018,8374647","journal-title":"Oxid Med Cell Longev"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"238","DOI":"10.2174\/138920211795860107","volume":"12","author":"Ferrari S.","year":"2011","unstructured":"Ferrari S.; Di Iorio E.; Barbaro V.; Ponzin D.; Sorrentino F.S.; Parmeggiani F.; Retinitis pigmentosa: genes and disease mechanisms. Curr Genomics 2011,12(4),238-249","journal-title":"Curr Genomics"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1111\/ceo.13434","volume":"47","author":"Murali A.","year":"2019","unstructured":"Murali A.; Ramlogan-Steel C.A.; Andrzejewski S.; Steel J.C.; Layton C.J.; Retinal explant culture: A platform to investigate human neuro-retina. Clin Exp Ophthalmol 2019,47(2),274-285","journal-title":"Clin Exp Ophthalmol"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"1776","DOI":"10.3390\/ijms22041776","volume":"22","author":"Pishavar E.","year":"2021","unstructured":"Pishavar E.; Luo H.; Bolander J.; Atala A.; Ramakrishna S.; Nanocarriers, progenitor cells, combinational approaches, and new insights on the retinal therapy. Int J Mol Sci 2021,22(4),1776","journal-title":"Int J Mol Sci"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"588","DOI":"10.3390\/cells10030588","volume":"10","author":"Holan V.","year":"2021","unstructured":"Holan V.; Palacka K.; Hermankova B.; Mesenchymal stem cell-based therapy for retinal degenerative diseases: Experimental models and clinical trials. Cells 2021,10(3),588","journal-title":"Cells"},{"key":"ref=16","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1007\/s40259-020-00453-8","volume":"34","author":"Fuller-Carter P.I.","year":"2020","unstructured":"Fuller-Carter P.I.; Basiri H.; Harvey A.R.; Carvalho L.S.; Focused update on AAV-based gene therapy clinical trials for inherited retinal degeneration. BioDrugs 2020,34(6),763-781","journal-title":"BioDrugs"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"634843","DOI":"10.3389\/fcell.2021.634843","volume":"9","author":"Zhu Q.","year":"2021","unstructured":"Zhu Q.; Rui X.; Li Y.; You Y.; Sheng X.L.; Lei B.; Identification of four novel variants and determination of genotype-phenotype correlations for ABCA4 variants associated with inherited retinal degenerations. Front Cell Dev Biol 2021,9,634843","journal-title":"Front Cell Dev Biol"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"1784","DOI":"10.4103\/1673-5374.280303","volume":"15","author":"Kutluer M.","year":"2020","unstructured":"Kutluer M.; Huang L.; Marigo V.; Targeting molecular pathways for the treatment of inherited retinal degeneration. Neural Regen Res 2020,15(10),1784-1791","journal-title":"Neural Regen Res"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"e161","DOI":"10.3346\/jkms.2019.34.e161","volume":"34","author":"Kim M.S.","year":"2019","unstructured":"Kim M.S.; Joo K.; Seong M.W.; Kim M.J.; Park K.H.; Park S.S.; Woo S.J.; Genetic mutation profiles in Korean patients with inherited retinal diseases. J Korean Med Sci 2019,34(21),e161","journal-title":"J Korean Med Sci"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"1384","DOI":"10.1016\/j.ophtha.2020.04.008","volume":"127","author":"Pontikos N.","year":"2020","unstructured":"Pontikos N.; Arno G.; Jurkute N.; Schiff E.; Ba-Abbad R.; Malka S.; Gimenez A.; Georgiou M.; Wright G.; Armengol M.; Knight H.; Katz M.; Moosajee M.; Yu-Wai-Man P.; Moore A.T.; Michaelides M.; Webster A.R.; Mahroo O.A.; Genetic basis of inherited retinal disease in a molecularly characterized cohort of more than 3000 families from the United Kingdom. Ophthalmology 2020,127(10),1384-1394","journal-title":"Ophthalmology"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"E1421","DOI":"10.3390\/genes11121421","volume":"11","author":"Sung Y.C.","year":"2020","unstructured":"Sung Y.C.; Yang C.H.; Yang C.M.; Lin C.W.; Huang D.S.; Huang Y.S.; Hu F.R.; Chen P.L.; Chen T.C.; Genotypes predispose phenotypes-clinical features and genetic spectrum of ABCA4-associated retinal dystrophies. Genes (Basel) 2020,11(12),E1421","journal-title":"Genes (Basel)"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"E5722","DOI":"10.3390\/ijms20225722","volume":"20","author":"Ziccardi L.","year":"2019","unstructured":"Ziccardi L.; Cordeddu V.; Gaddini L.; Matteucci A.; Parravano M.; Malchiodi-Albedi F.; Varano M.; Gene therapy in retinal dystrophies. Int J Mol Sci 2019,20(22),E5722","journal-title":"Int J Mol Sci"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1038\/309253a0","volume":"309","author":"Bhattacharya S.S.","year":"1984","unstructured":"Bhattacharya S.S.; Wright A.F.; Clayton J.F.; Price W.H.; Phillips C.I.; McKeown C.M.; Jay M.; Bird A.C.; Pearson P.L.; Southern E.M.; Close genetic linkage between X-linked retinitis pigmentosa and a restriction fragment length polymorphism identified by recombinant DNA probe L1.28. Nature 1984,309(5965),253-255","journal-title":"Nature"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"760","DOI":"10.3390\/biom11050760","volume":"11","author":"Tuohy G.P.","year":"2021","unstructured":"Tuohy G.P.; Megaw R.; A systematic review and meta-analyses of interventional clinical trial studies for gene therapies for the Inherited Retinal Degenerations (IRDs). Biomolecules 2021,11(5),760","journal-title":"Biomolecules"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/j.preteyeres.2010.03.004","volume":"29","author":"Berger W.","year":"2010","unstructured":"Berger W.; Kloeckener-Gruissem B.; Neidhardt J.; The molecular basis of human retinal and vitreoretinal diseases. Prog Retin Eye Res 2010,29(5),335-375","journal-title":"Prog Retin Eye Res"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.preteyeres.2017.10.004","volume":"63","author":"Dias M.F.","year":"2018","unstructured":"Dias M.F.; Joo K.; Kemp J.A.; Fialho S.L.; da Silva Cunha A.; Woo S.J.; Kwon Y.J.; Molecular genetics and emerging therapies for retinitis pigmentosa: Basic research and clinical perspectives. Prog Retin Eye Res 2018,63,107-131","journal-title":"Prog Retin Eye Res"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"1514","DOI":"10.1002\/humu.24064","volume":"41","author":"Weisschuh N.","year":"2020","unstructured":"Weisschuh N.; Obermaier C.D.; Battke F.; Bernd A.; Kuehlewein L.; Nasser F.; Zobor D.; Zrenner E.; Weber E.; Wissinger B.; Biskup S.; Stingl K.; Kohl S.; Genetic architecture of inherited retinal degeneration in Germany: A large cohort study from a single diagnostic center over a 9-year period. Hum Mutat 2020,41(9),1514-1527","journal-title":"Hum Mutat"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1186\/s12920-021-00874-6","volume":"14","author":"Ma D.J.","year":"2021","unstructured":"Ma D.J.; Lee H.S.; Kim K.; Choi S.; Jang I.; Cho S.H.; Yoon C.K.; Lee E.K.; Yu H.G.; Whole-exome sequencing in 168 Korean patients with inherited retinal degeneration. BMC Med Genomics 2021,14(1),74","journal-title":"BMC Med Genomics"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1038\/s41525-021-00180-1","volume":"6","author":"Chen T.C.","year":"2021","unstructured":"Chen T.C.; Huang D.S.; Lin C.W.; Yang C.H.; Yang C.M.; Wang V.Y.; Lin J.W.; Luo A.C.; Hu F.R.; Chen P.L.; Genetic characteristics and epidemiology of inherited retinal degeneration in Taiwan. NPJ Genom Med 2021,6(1),16","journal-title":"NPJ Genom Med"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"1795","DOI":"10.1016\/S0140-6736(06)69740-7","volume":"368","author":"Hartong D.T.","year":"2006","unstructured":"Hartong D.T.; Berson E.L.; Dryja T.P.; Retinitis pigmentosa. Lancet 2006,368(9549),1795-1809","journal-title":"Lancet"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1136\/jmg.29.5.289","volume":"29","author":"Moore A.T.","year":"1992","unstructured":"Moore A.T.; Cone and cone-rod dystrophies. J Med Genet 1992,29(5),289-290","journal-title":"J Med Genet"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1097\/IAE.0000000000001341","volume":"37","author":"Hafler B.P.","year":"2017","unstructured":"Hafler B.P.; Clinical progress in inherited retinal degenerations: Gene therapy clinical trials and advances in genetic sequencing. Retina 2017,37(3),417-423","journal-title":"Retina"},{"key":"ref=33","first-page":"139","volume":"4","author":"Nash B.M.","year":"2015","unstructured":"Nash B.M.; Wright D.C.; Grigg J.R.; Bennetts B.; Jamieson R.V.; Retinal dystrophies, genomic applications in diagnosis and prospects for therapy. Transl Pediatr 2015,4(2),139-163","journal-title":"Transl Pediatr"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/S0039-6257(98)00046-0","volume":"43","author":"van Soest S.","year":"1999","unstructured":"van Soest S.; Westerveld A.; de Jong P.T.; Bleeker-Wagemakers E.M.; Bergen A.A.; Retinitis pigmentosa: Defined from a molecular point of view. Surv Ophthalmol 1999,43(4),321-334","journal-title":"Surv Ophthalmol"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1023\/A:1015183500719","volume":"21","author":"Lev S.","year":"2001","unstructured":"Lev S.; Molecular aspects of retinal degenerative diseases. Cell Mol Neurobiol 2001,21(6),575-589","journal-title":"Cell Mol Neurobiol"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1097\/ICU.0000000000000660","volume":"31","author":"Prado D.A.","year":"2020","unstructured":"Prado D.A.; Acosta-Acero M.; Maldonado R.S.; Gene therapy beyond luxturna: A new horizon of the treatment for inherited retinal disease. Curr Opin Ophthalmol 2020,31(3),147-154","journal-title":"Curr Opin Ophthalmol"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"e95768","DOI":"10.1371\/journal.pone.0095768","volume":"9","author":"Manes G.","year":"2014","unstructured":"Manes G.; Cheguru P.; Majumder A.; Bocquet B.; S\u00e9n\u00e9chal A.; Artemyev N.O.; Hamel C.P.; Brabet P.; A truncated form of rod photoreceptor PDE6 \u03b2-subunit causes autosomal dominant congenital stationary night blindness by interfering with the inhibitory activity of the \u03b3-subunit. PLoS One 2014,9(4),e95768","journal-title":"PLoS One"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"7694801","DOI":"10.1155\/2018\/7694801","volume":"2018","author":"Zeitz C.","year":"2018","unstructured":"Zeitz C.; M\u00e9j\u00e9case C.; St\u00e9venard M.; Michiels C.; Audo I.; Marmor M.F.; A novel heterozygous missense mutation in GNAT1 leads to autosomal dominant riggs type of congenital stationary night blindness. BioMed Res Int 2018,2018,7694801","journal-title":"BioMed Res Int"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1167\/iovs.11-8026","volume":"53","author":"Naeem M.A.","year":"2012","unstructured":"Naeem M.A.; Chavali V.R.; Ali S.; Iqbal M.; Riazuddin S.; Khan S.N.; Husnain T.; Sieving P.A.; Ayyagari R.; Riazuddin S.; Hejtmancik J.F.; Riazuddin S.A.; GNAT1 associated with autosomal recessive congenital stationary night blindness. Invest Ophthalmol Vis Sci 2012,53(3),1353-1361","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"635216","DOI":"10.3389\/fcell.2021.635216","volume":"9","author":"Meng X.","year":"2021","unstructured":"Meng X.; Long Y.; Ren J.; Wang G.; Yin X.; Li S.; Ocular characteristics of patients with Bardet-Biedl syndrome caused by pathogenic BBS gene variation in a Chinese Cohort. Front Cell Dev Biol 2021,9,635216","journal-title":"Front Cell Dev Biol"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"e1006936","DOI":"10.1371\/journal.pgen.1006936","volume":"13","author":"Scott C.A.","year":"2017","unstructured":"Scott C.A.; Marsden A.N.; Rebagliati M.R.; Zhang Q.; Chamling X.; Searby C.C.; Baye L.M.; Sheffield V.C.; Slusarski D.C.; Nuclear\/cytoplasmic transport defects in BBS6 underlie congenital heart disease through perturbation of a chromatin remodeling protein. PLoS Genet 2017,13(7),e1006936","journal-title":"PLoS Genet"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1002\/humu.21337","volume":"31","author":"Coppieters F.","year":"2010","unstructured":"Coppieters F.; Lefever S.; Leroy B.P.; De Baere E.; CEP290, a gene with many faces: Mutation overview and presentation of CEP290base. Hum Mutat 2010,31(10),1097-1108","journal-title":"Hum Mutat"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"E557","DOI":"10.3390\/ijms20030557","volume":"20","author":"L\u00e9veillard T.","year":"2019","unstructured":"L\u00e9veillard T.; Klipfel L.; Mechanisms underlying the visual benefit of cell transplantation for the treatment of retinal degenerations. Int J Mol Sci 2019,20(3),E557","journal-title":"Int J Mol Sci"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1007\/BF00763096","volume":"26","author":"Wallace D.C.","year":"1994","unstructured":"Wallace D.C.; Mitochondrial DNA mutations in diseases of energy metabolism. J Bioenerg Biomembr 1994,26(3),241-250","journal-title":"J Bioenerg Biomembr"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"1751","DOI":"10.4103\/1673-5374.306063","volume":"16","author":"Ross M.","year":"2021","unstructured":"Ross M.; Ofri R.; The future of retinal gene therapy: evolving from subretinal to intravitreal vector delivery. Neural Regen Res 2021,16(9),1751-1759","journal-title":"Neural Regen Res"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1111\/ceo.13416","volume":"47","author":"Ramlogan-Steel C.A.","year":"2019","unstructured":"Ramlogan-Steel C.A.; Murali A.; Andrzejewski S.; Dhungel B.; Steel J.C.; Layton C.J.; Gene therapy and the adeno-associated virus in the treatment of genetic and acquired ophthalmic diseases in humans: Trials, future directions and safety considerations. Clin Exp Ophthalmol 2019,47(4),521-536","journal-title":"Clin Exp Ophthalmol"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1089\/hum.2015.147","volume":"27","author":"Dalkara D.","year":"2016","unstructured":"Dalkara D.; Goureau O.; Marazova K.; Sahel J.A.; Let there be light: Gene and cell therapy for blindness. Hum Gene Ther 2016,27(2),134-147","journal-title":"Hum Gene Ther"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1016\/j.molmed.2018.06.006","volume":"24","author":"Trapani I.","year":"2018","unstructured":"Trapani I.; Auricchio A.; Seeing the light after 25 years of retinal gene therapy. Trends Mol Med 2018,24(8),669-681","journal-title":"Trends Mol Med"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1089\/hum.2020.070","volume":"31","author":"Frederick A.","year":"2020","unstructured":"Frederick A.; Sullivan J.; Liu L.; Adamowicz M.; Lukason M.; Raymer J.; Luo Z.; Jin X.; Rao K.N.; O\u2019Riordan C.; Engineered capsids for efficient gene delivery to the retina and cornea. Hum Gene Ther 2020,31(13-14),756-774","journal-title":"Hum Gene Ther"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"1733","DOI":"10.1096\/fj.201700982R","volume":"32","author":"Gruntman A.M.","year":"2018","unstructured":"Gruntman A.M.; Flotte T.R.; The rapidly evolving state of gene therapy. FASEB J 2018,32(4),1733-1740","journal-title":"FASEB J"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"051002","DOI":"10.1088\/1741-2552\/aa7a27","volume":"14","author":"Gupta P.R.","year":"2017","unstructured":"Gupta P.R.; Huckfeldt R.M.; Gene therapy for inherited retinal degenerations: Initial successes and future challenges. J Neural Eng 2017,14(5),051002","journal-title":"J Neural Eng"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1146\/annurev-vision-102016-061413","volume":"3","author":"Planul A.","year":"2017","unstructured":"Planul A.; Dalkara D.; Vectors and gene delivery to the retina. Annu Rev Vis Sci 2017,3,121-140","journal-title":"Annu Rev Vis Sci"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1038\/gt.2014.115","volume":"22","author":"Kotterman M.A.","year":"2015","unstructured":"Kotterman M.A.; Yin L.; Strazzeri J.M.; Flannery J.G.; Merigan W.H.; Schaffer D.V.; Antibody neutralization poses a barrier to intravitreal adeno-associated viral vector gene delivery to non-human primates. Gene Ther 2015,22(2),116-126","journal-title":"Gene Ther"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"100975","DOI":"10.1016\/j.preteyeres.2021.100975","volume":"6","author":"Botto C.","year":"2021","unstructured":"Botto C.; Rucli M.; Tekinsoy M.D.; Pulman J.; Sahel J.A.; Dalkara D.; Early and late stage gene therapy interventions for inherited retinal degenerations. Prog Retin Eye Res 2021,6,100975","journal-title":"Prog Retin Eye Res"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1159\/000479157","volume":"58","author":"Peng Y.","year":"2017","unstructured":"Peng Y.; Tang L.; Zhou Y.; Subretinal injection: A review on the novel route of therapeutic delivery for vitreoretinal diseases. Ophthalmic Res 2017,58(4),217-226","journal-title":"Ophthalmic Res"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1136\/bjophthalmol-2020-318483","volume":"106","author":"Daich Varela M.","year":"2022","unstructured":"Daich Varela M.; Cabral de Guimaraes T.A.; Georgiou M.; Michaelides M.; Leber congenital amaurosis\/early-onset severe retinal dystrophy: Current management and clinical trials. Br J Ophthalmol 2022,106(4),445-451","journal-title":"Br J Ophthalmol"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1038\/s41573-019-0012-9","volume":"18","author":"Wang D.","year":"2019","unstructured":"Wang D.; Tai P.W.L.; Gao G.; Adeno-associated virus vector as a platform for gene therapy delivery. Nat Rev Drug Discov 2019,18(5),358-378","journal-title":"Nat Rev Drug Discov"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1007\/s11095-018-2554-7","volume":"36","author":"Rodrigues G.A.","year":"2018","unstructured":"Rodrigues G.A.; Shalaev E.; Karami T.K.; Cunningham J.; Slater N.K.H.; Rivers H.M.; Pharmaceutical development of AAV-based gene therapy products for the eye. Pharm Res 2018,36(2),29","journal-title":"Pharm Res"},{"key":"ref=59","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1038\/gt.2009.20","volume":"16","author":"Stewart H.J.","year":"2009","unstructured":"Stewart H.J.; Leroux-Carlucci M.A.; Sion C.J.; Mitrophanous K.A.; Radcliffe P.A.; Development of inducible EIAV-based lentiviral vector packaging and producer cell lines. Gene Ther 2009,16(6),805-814","journal-title":"Gene Ther"},{"key":"ref=60","doi-asserted-by":"publisher","first-page":"e201","DOI":"10.1371\/journal.pmed.0030201","volume":"3","author":"Williams M.L.","year":"2006","unstructured":"Williams M.L.; Coleman J.E.; Haire S.E.; Aleman T.S.; Cideciyan A.V.; Sokal I.; Palczewski K.; Jacobson S.G.; Semple-Rowland S.L.; Lentiviral expression of retinal guanylate cyclase-1 (RetGC1) restores vision in an avian model of childhood blindness. PLoS Med 2006,3(6),e201","journal-title":"PLoS Med"},{"key":"ref=61","doi-asserted-by":"publisher","first-page":"e20553","DOI":"10.1371\/journal.pone.0020553","volume":"6","author":"Verrier J.D.","year":"2011","unstructured":"Verrier J.D.; Madorsky I.; Coggin W.E.; Geesey M.; Hochman M.; Walling E.; Daroszewski D.; Eccles K.S.; Ludlow R.; Semple-Rowland S.L.; Bicistronic lentiviruses containing a viral 2A cleavage sequence reliably co-express two proteins and restore vision to an animal model of LCA1. PLoS One 2011,6(5),e20553","journal-title":"PLoS One"},{"key":"ref=62","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1016\/j.ymeth.2013.06.026","volume":"66","author":"Semple-Rowland S.L.","year":"2014","unstructured":"Semple-Rowland S.L.; Berry J.; Use of lentiviral vectors to deliver and express bicistronic transgenes in developing chicken embryos. Methods 2014,66(3),466-473","journal-title":"Methods"},{"key":"ref=63","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1126\/science.1190897","volume":"329","author":"Busskamp V.","year":"2010","unstructured":"Busskamp V.; Duebel J.; Balya D.; Fradot M.; Viney T.J.; Siegert S.; Groner A.C.; Cabuy E.; Forster V.; Seeliger M.; Biel M.; Humphries P.; Paques M.; Mohand-Said S.; Trono D.; Deisseroth K.; Sahel J.A.; Picaud S.; Roska B.; Genetic reactivation of cone photoreceptors restores visual responses in retinitis pigmentosa. Science 2010,329(5990),413-417","journal-title":"Science"},{"key":"ref=64","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.15252\/emmm.201505699","volume":"8","author":"Sengupta A.","year":"2016","unstructured":"Sengupta A.; Chaffiol A.; Mac\u00e9 E.; Caplette R.; Desrosiers M.; Lampi\u010d M.; Forster V.; Marre O.; Lin J.Y.; Sahel J.A.; Picaud S.; Dalkara D.; Duebel J.; Red-shifted channelrhodopsin stimulation restores light responses in blind mice, macaque retina, and human retina. EMBO Mol Med 2016,8(11),1248-1264","journal-title":"EMBO Mol Med"},{"key":"ref=65","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.visres.2014.07.013","volume":"111","author":"Carvalho LS","year":"2015","unstructured":"Carvalho LS; Vandenberghe LH; Promising and delivering gene therapies for vision loss. Vision research 2015,111(Pt B),124-133","journal-title":"Vision research"},{"key":"ref=66","first-page":"523","volume":"90","author":"Chan L.","year":"2017","unstructured":"Chan L.; Mahajan V.B.; Tsang S.H.; Genome surgery and gene therapy in retinal disorders. Yale J Biol Med 2017,90(4),523-532","journal-title":"Yale J Biol Med"},{"key":"ref=67","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1089\/hum.2015.025","volume":"26","author":"Hastie E.","year":"2015","unstructured":"Hastie E.; Samulski R.J.; Adeno-associated virus at 50: A golden anniversary of discovery, research, and gene therapy success--a personal perspective. Hum Gene Ther 2015,26(5),257-265","journal-title":"Hum Gene Ther"},{"key":"ref=68","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1016\/j.ejpb.2014.12.028","volume":"95","author":"Adijanto J.","year":"2015","unstructured":"Adijanto J.; Naash M.I.; Nanoparticle-based technologies for retinal gene therapy. Eur J Pharm Biopharm 2015,95(Pt B),353-367","journal-title":"Eur J Pharm Biopharm"},{"key":"ref=69","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.1016\/j.drudis.2019.05.038","volume":"24","author":"Bordet T.","year":"2019","unstructured":"Bordet T.; Behar-Cohen F.; Ocular gene therapies in clinical practice: Viral vectors and nonviral alternatives. Drug Discov Today 2019,24(8),1685-1693","journal-title":"Drug Discov Today"},{"key":"ref=70","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.preteyeres.2014.08.001","volume":"43","author":"Trapani I.","year":"2014","unstructured":"Trapani I.; Puppo A.; Auricchio A.; Vector platforms for gene therapy of inherited retinopathies. Prog Retin Eye Res 2014,43,108-128","journal-title":"Prog Retin Eye Res"},{"key":"ref=71","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1080\/13543784.2020.1804853","volume":"29","author":"Xue K.","year":"2020","unstructured":"Xue K.; MacLaren R.E.; Antisense oligonucleotide therapeutics in clinical trials for the treatment of inherited retinal diseases. Expert Opin Investig Drugs 2020,29(10),1163-1170","journal-title":"Expert Opin Investig Drugs"},{"key":"ref=72","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1002\/mus.26001","volume":"57","author":"Goyal N.","year":"2018","unstructured":"Goyal N.; Narayanaswami P.; Making sense of antisense oligonucleotides: A narrative review. Muscle Nerve 2018,57(3),356-370","journal-title":"Muscle Nerve"},{"key":"ref=73","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1517\/13543784.6.9.1157","volume":"6","author":"Temsamani J.","year":"1997","unstructured":"Temsamani J.; Pari G.S.; Guinot P.; Antisense approach for the treatment of cytomegalovirus infection. Expert Opin Investig Drugs 1997,6(9),1157-1167","journal-title":"Expert Opin Investig Drugs"},{"key":"ref=74","doi-asserted-by":"publisher","first-page":"1380","DOI":"10.1016\/j.cell.2013.08.021","volume":"154","author":"Ran F.A.","year":"2013","unstructured":"Ran F.A.; Hsu P.D.; Lin C.Y.; Gootenberg J.S.; Konermann S.; Trevino A.E.; Scott D.A.; Inoue A.; Matoba S.; Zhang Y.; Zhang F.; Double nicking by RNA-guided CRISPR Cas9 for enhanced genome editing specificity. Cell 2013,154(6),1380-1389","journal-title":"Cell"},{"key":"ref=75","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.cell.2016.10.044","volume":"168","author":"Komor A.C.","year":"2017","unstructured":"Komor A.C.; Badran A.H.; Liu D.R.; CRISPR-based technologies for the manipulation of eukaryotic genomes. Cell 2017,168(1-2),20-36","journal-title":"Cell"},{"key":"ref=76","first-page":"533","volume":"90","author":"Peddle C.F.","year":"2017","unstructured":"Peddle C.F.; MacLaren R.E.; The application of CRISPR\/Cas9 for the treatment of retinal diseases. Yale J Biol Med 2017,90(4),533-541","journal-title":"Yale J Biol Med"},{"key":"ref=77","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.addr.2020.06.011","volume":"168","author":"Yu W.","year":"2021","unstructured":"Yu W.; Wu Z.; Ocular delivery of CRISPR\/Cas genome editing components for treatment of eye diseases. Adv Drug Deliv Rev 2021,168,181-195","journal-title":"Adv Drug Deliv Rev"},{"key":"ref=78","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1016\/j.ymthe.2017.05.015","volume":"25","author":"Burnight E.R.","year":"2017","unstructured":"Burnight E.R.; Gupta M.; Wiley L.A.; Anfinson K.R.; Tran A.; Triboulet R.; Using CRISPR-Cas9 to generate gene-corrected autologous ipscs for the treatment of inherited retinal degeneration. Mol Ther 2017,25(9),1999-2013","journal-title":"Mol Ther"},{"key":"ref=79","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1002\/ajmg.c.31842","volume":"184","author":"Ku C.A.","year":"2020","unstructured":"Ku C.A.; Pennesi M.E.; The new landscape of retinal gene therapy. Am J Med Genet C Semin Med Genet 2020,184(3),846-859","journal-title":"Am J Med Genet C Semin Med Genet"},{"key":"ref=80","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1111\/dgd.12704","volume":"63","author":"Uyama H.","year":"2021","unstructured":"Uyama H.; Mandai M.; Takahashi M.; Stem-cell-based therapies for retinal degenerative diseases: Current challenges in the establishment of new treatment strategies. Dev Growth Differ 2021,63(1),59-71","journal-title":"Dev Growth Differ"},{"key":"ref=81","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1186\/s12967-017-1183-y","volume":"15","author":"Tang Z.","year":"2017","unstructured":"Tang Z.; Zhang Y.; Wang Y.; Zhang D.; Shen B.; Luo M.; Gu P.; Progress of stem\/progenitor cell-based therapy for retinal degeneration. J Transl Med 2017,15(1),99","journal-title":"J Transl Med"},{"key":"ref=82","doi-asserted-by":"publisher","first-page":"368rv6","DOI":"10.1126\/scitranslmed.aaf2838","volume":"8","author":"Scholl H.P.","year":"2016","unstructured":"Scholl H.P.; Strauss R.W.; Singh M.S.; Dalkara D.; Roska B.; Picaud S.; Sahel J.A.; Emerging therapies for inherited retinal degeneration. Sci Transl Med 2016,8(368),368rv6","journal-title":"Sci Transl Med"},{"key":"ref=83","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1016\/j.jcyt.2016.03.001","volume":"18","author":"Li Z.","year":"2016","unstructured":"Li Z.; Zeng Y.; Chen X.; Li Q.; Wu W.; Xue L.; Xu H.; Yin Z.Q.; Neural stem cells transplanted to the subretinal space of rd1 mice delay retinal degeneration by suppressing microglia activation. Cytotherapy 2016,18(6),771-784","journal-title":"Cytotherapy"},{"key":"ref=84","doi-asserted-by":"publisher","first-page":"E1406","DOI":"10.3390\/ijms18081406","volume":"18","author":"Ding S.L.S.","year":"2017","unstructured":"Ding S.L.S.; Kumar S.; Mok P.L.; Cellular reparative mechanisms of mesenchymal stem cells for retinal diseases. Int J Mol Sci 2017,18(8),E1406","journal-title":"Int J Mol Sci"},{"key":"ref=85","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1007\/s12015-016-9706-0","volume":"13","author":"Enzmann V.","year":"2017","unstructured":"Enzmann V.; Lecaud\u00e9 S.; Kruschinski A.; Vater A.; CXCL12\/SDF-1-dependent retinal migration of endogenous bone marrow-derived stem cells improves visual function after pharmacologically induced retinal degeneration. Stem Cell Rev Rep 2017,13(2),278-286","journal-title":"Stem Cell Rev Rep"},{"key":"ref=86","doi-asserted-by":"publisher","first-page":"2586","DOI":"10.1167\/iovs.17-23646","volume":"59","author":"McLelland B.T.","year":"2018","unstructured":"McLelland B.T.; Lin B.; Mathur A.; Aramant R.B.; Thomas B.B.; Nistor G.; Keirstead H.S.; Seiler M.J.; Transplanted hESC-derived retina organoid sheets differentiate, integrate, and improve visual function in retinal degenerate rats. Invest Ophthalmol Vis Sci 2018,59(6),2586-2603","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"ref=87","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.preteyeres.2018.11.003","volume":"69","author":"Jin Z.B.","year":"2019","unstructured":"Jin Z.B.; Gao M.L.; Deng W.L.; Wu K.C.; Sugita S.; Mandai M.; Takahashi M.; Stemming retinal regeneration with pluripotent stem cells. Prog Retin Eye Res 2019,69,38-56","journal-title":"Prog Retin Eye Res"},{"key":"ref=88","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s40942-019-0158-y","volume":"5","author":"Ludwig P.E.","year":"2019","unstructured":"Ludwig P.E.; Freeman S.C.; Janot A.C.; Novel stem cell and gene therapy in diabetic retinopathy, age related macular degeneration, and retinitis pigmentosa. Int J Retina Vitreous 2019,5,7","journal-title":"Int J Retina Vitreous"},{"key":"ref=89","doi-asserted-by":"publisher","first-page":"173","DOI":"10.4103\/1673-5374.200793","volume":"12","author":"Aharony I.","year":"2017","unstructured":"Aharony I.; Michowiz S.; Goldenberg-Cohen N.; The promise of stem cell-based therapeutics in ophthalmology. Neural Regen Res 2017,12(2),173-180","journal-title":"Neural Regen Res"},{"key":"ref=90","doi-asserted-by":"publisher","first-page":"e106","DOI":"10.1016\/S2214-109X(13)70145-1","volume":"2","author":"Wong W.L.","year":"2014","unstructured":"Wong W.L.; Su X.; Li X.; Cheung C.M.; Klein R.; Cheng C.Y.; Wong T.Y.; Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: A systematic review and meta-analysis. Lancet Glob Health 2014,2(2),e106-e116","journal-title":"Lancet Glob Health"},{"key":"ref=91","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.jtos.2015.11.004","volume":"14","author":"Coulson-Thomas V.J.","year":"2016","unstructured":"Coulson-Thomas V.J.; Coulson-Thomas Y.M.; Gesteira T.F.; Kao W.W.; Extrinsic and intrinsic mechanisms by which mesenchymal stem cells suppress the immune system. Ocul Surf 2016,14(2),121-134","journal-title":"Ocul Surf"},{"key":"ref=92","doi-asserted-by":"publisher","first-page":"1805","DOI":"10.1016\/j.stemcr.2021.06.002","volume":"16","author":"He X.Y.","year":"2021","unstructured":"He X.Y.; Zhao C.J.; Xu H.; Chen K.; Bian B.S.; Gong Y.; Weng C.H.; Zeng Y.X.; Fu Y.; Liu Y.; Yin Z.Q.; Synaptic repair and vision restoration in advanced degenerating eyes by transplantation of retinal progenitor cells. Stem Cell Reports 2021,16(7),1805-1817","journal-title":"Stem Cell Reports"},{"key":"ref=93","doi-asserted-by":"publisher","first-page":"1754","DOI":"10.1080\/15384101.2020.1777805","volume":"19","author":"Gao H.","year":"2020","unstructured":"Gao H.; Ni N.; Zhang D.; Wang Y.; Tang Z.; Sun N.; Ju Y.; Dai X.; Zhang Y.; Liu Y.; Gu P.; miR-762 regulates the proliferation and differentiation of retinal progenitor cells by targeting NPDC1. Cell Cycle 2020,19(14),1754-1767","journal-title":"Cell Cycle"},{"key":"ref=94","doi-asserted-by":"publisher","first-page":"265","DOI":"10.3389\/fncel.2020.00265","volume":"14","author":"Eintracht J.","year":"2020","unstructured":"Eintracht J.; Toms M.; Moosajee M.; The use of induced pluripotent stem cells as a model for developmental eye disorders. Front Cell Neurosci 2020,14,265","journal-title":"Front Cell Neurosci"},{"key":"ref=95","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1002\/sctm.20-0242","volume":"10","author":"Jha B.S.","year":"2021","unstructured":"Jha B.S.; Farnoodian M.; Bharti K.; Regulatory considerations for developing a phase I investigational new drug application for autologous induced pluripotent stem cells-based therapy product. Stem Cells Transl Med 2021,10(2),198-208","journal-title":"Stem Cells Transl Med"},{"key":"ref=96","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1007\/978-3-030-66014-7_11","volume":"1256","author":"Khateb S.","year":"2021","unstructured":"Khateb S.; Jha S.; Bharti K.; Banin E.; Cell-based therapies for age-related macular degeneration. Adv Exp Med Biol 2021,1256,265-293","journal-title":"Adv Exp Med Biol"},{"key":"ref=97","doi-asserted-by":"publisher","first-page":"e12310","DOI":"10.1111\/cpr.12310","volume":"50","author":"Li X.L.","year":"2017","unstructured":"Li X.L.; Zeng D.; Chen Y.; Ding L.; Li W.J.; Wei T.; Ou D.B.; Yan S.; Wang B.; Zheng Q.S.; Role of alpha- and beta-adrenergic receptors in cardiomyocyte differentiation from murine-induced pluripotent stem cells. Cell Prolif 2017,50(1),e12310","journal-title":"Cell Prolif"},{"key":"ref=98","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1038\/s41419-020-02955-3","volume":"11","author":"Wang Y.","year":"2020","unstructured":"Wang Y.; Tang Z.; Gu P.; Stem\/progenitor cell-based transplantation for retinal degeneration: A review of clinical trials. Cell Death Dis 2020,11(9),793","journal-title":"Cell Death Dis"},{"key":"ref=99","doi-asserted-by":"publisher","first-page":"632","DOI":"10.4252\/wjsc.v13.i6.632","volume":"13","author":"Mannino G.","year":"2021","unstructured":"Mannino G.; Russo C.; Longo A.; Anfuso C.D.; Lupo G.; Lo Furno D.; Giuffrida R.; Giurdanella G.; Potential therapeutic applications of mesenchymal stem cells for the treatment of eye diseases. World J Stem Cells 2021,13(6),632-644","journal-title":"World J Stem Cells"},{"key":"ref=100","doi-asserted-by":"publisher","first-page":"E1784","DOI":"10.3390\/ijms20071784","volume":"20","author":"Ding S.S.L.","year":"2019","unstructured":"Ding S.S.L.; Subbiah S.K.; Khan M.S.A.; Farhana A.; Mok P.L.; Empowering mesenchymal stem cells for ocular degenerative disorders. Int J Mol Sci 2019,20(7),E1784","journal-title":"Int J Mol Sci"},{"key":"ref=101","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.tice.2018.01.005","volume":"51","author":"Li Y.","year":"2018","unstructured":"Li Y.; Zhang Y.; Qi S.; Su G.; Retinal organotypic culture - A candidate for research on retinas. Tissue Cell 2018,51,1-7","journal-title":"Tissue Cell"},{"key":"ref=102","doi-asserted-by":"publisher","first-page":"3309","DOI":"10.1167\/iovs.10-6873","volume":"52","author":"Bull N.D.","year":"2011","unstructured":"Bull N.D.; Johnson T.V.; Welsapar G.; DeKorver N.W.; Tomarev S.I.; Martin K.R.; Use of an adult rat retinal explant model for screening of potential retinal ganglion cell neuroprotective therapies. Invest Ophthalmol Vis Sci 2011,52(6),3309-3320","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"ref=103","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1177\/1470320314566018","volume":"16","author":"White A.J.","year":"2015","unstructured":"White A.J.; Heller J.P.; Leung J.; Tassoni A.; Martin K.R.; Retinal ganglion cell neuroprotection by an angiotensin II blocker in an ex vivo retinal explant model. J Renin Angiotensin Aldosterone Syst 2015,16(4),1193-1201","journal-title":"J Renin Angiotensin Aldosterone Syst"},{"key":"ref=104","doi-asserted-by":"publisher","first-page":"E1584","DOI":"10.3390\/ijms17091584","volume":"17","author":"Kimura A.","year":"2016","unstructured":"Kimura A.; Namekata K.; Guo X.; Harada C.; Harada T.; Neuroprotection, growth factors and BDNF-TrkB signalling in retinal degeneration. Int J Mol Sci 2016,17(9),E1584","journal-title":"Int J Mol Sci"},{"key":"ref=105","doi-asserted-by":"publisher","first-page":"2487473","DOI":"10.1155\/2018\/2487473","volume":"2018","author":"Smedowski A.","year":"2018","unstructured":"Smedowski A.; Pietrucha-Dutczak M.; Maniar R.; Ajeleti M.; Matuszek I.; Lewin-Kowalik J.; FluoroGold-Labeled organotypic retinal explant culture for neurotoxicity screening studies. Oxid Med Cell Longev 2018,2018,2487473","journal-title":"Oxid Med Cell Longev"},{"key":"ref=106","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1016\/j.exer.2008.12.002","volume":"88","author":"McKinnon S.J.","year":"2009","unstructured":"McKinnon S.J.; Schlamp C.L.; Nickells R.W.; Mouse models of retinal ganglion cell death and glaucoma. Exp Eye Res 2009,88(4),816-824","journal-title":"Exp Eye Res"},{"key":"ref=107","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.exer.2016.07.010","volume":"151","author":"Pattamatta U.","year":"2016","unstructured":"Pattamatta U.; McPherson Z.; White A.; A mouse retinal explant model for use in studying neuroprotection in glaucoma. Exp Eye Res 2016,151,38-44","journal-title":"Exp Eye Res"},{"key":"ref=108","doi-asserted-by":"publisher","first-page":"E9391","DOI":"10.1073\/pnas.1808903115","volume":"115","author":"Singh H.P.","year":"2018","unstructured":"Singh H.P.; Wang S.; Stachelek K.; Lee S.; Reid M.W.; Thornton M.E.; Craft C.M.; Grubbs B.H.; Cobrinik D.; Developmental stage-specific proliferation and retinoblastoma genesis in RB-deficient human but not mouse cone precursors. Proc Natl Acad Sci USA 2018,115(40),E9391-E9400","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=109","doi-asserted-by":"publisher","first-page":"503","DOI":"10.3109\/02713683.2013.763989","volume":"38","author":"Taylor L.","year":"2013","unstructured":"Taylor L.; Arn\u00e9r K.; Engelsberg K.; Ghosh F.; Effects of glial cell line-derived neurotrophic factor on the cultured adult full-thickness porcine retina. Curr Eye Res 2013,38(4),503-515","journal-title":"Curr Eye Res"},{"key":"ref=110","doi-asserted-by":"publisher","first-page":"154712","DOI":"10.1016\/j.metabol.2021.154712","volume":"117","author":"Yang G.","year":"2021","unstructured":"Yang G.; Wei J.; Liu P.; Zhang Q.; Tian Y.; Hou G.; Meng L.; Xin Y.; Jiang X.; Role of the gut microbiota in type 2 diabetes and related diseases. Metabolism 2021,117,154712","journal-title":"Metabolism"},{"key":"ref=111","doi-asserted-by":"publisher","first-page":"1876","DOI":"10.1016\/j.bbadis.2018.09.032","volume":"1865","author":"Fernandes R.","year":"2019","unstructured":"Fernandes R.; Viana S.D.; Nunes S.; Reis F.; Diabetic gut microbiota dysbiosis as an inflammaging and immunosenescence condition that fosters progression of retinopathy and nephropathy. Biochim Biophys Acta Mol Basis Dis 2019,1865(7),1876-1897","journal-title":"Biochim Biophys Acta Mol Basis Dis"},{"key":"ref=112","doi-asserted-by":"publisher","first-page":"40826","DOI":"10.1038\/srep40826","volume":"7","author":"Zinkernagel M.S.","year":"2017","unstructured":"Zinkernagel M.S.; Zysset-Burri D.C.; Keller I.; Berger L.E.; Leichtle A.B.; Largiad\u00e8r C.R.; Fiedler G.M.; Wolf S.; Association of the intestinal microbiome with the development of neovascular age-related macular degeneration. Sci Rep 2017,7,40826","journal-title":"Sci Rep"},{"key":"ref=113","doi-asserted-by":"publisher","first-page":"E4472","DOI":"10.1073\/pnas.1702302114","volume":"114","author":"Rowan S.","year":"2017","unstructured":"Rowan S.; Jiang S.; Korem T.; Szymanski J.; Chang M.L.; Szelog J.; Cassalman C.; Dasuri K.; McGuire C.; Nagai R.; Du X.L.; Brownlee M.; Rabbani N.; Thornalley P.J.; Baleja J.D.; Deik A.A.; Pierce K.A.; Scott J.M.; Clish C.B.; Smith D.E.; Weinberger A.; Avnit-Sagi T.; Lotan-Pompan M.; Segal E.; Taylor A.; Involvement of a gut-retina axis in protection against dietary glycemia-induced age-related macular degeneration. Proc Natl Acad Sci USA 2017,114(22),E4472-E4481","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=114","doi-asserted-by":"publisher","first-page":"107921","DOI":"10.1016\/j.exer.2020.107921","volume":"191","author":"Gong H.","year":"2020","unstructured":"Gong H.; Zhang S.; Li Q.; Zuo C.; Gao X.; Zheng B.; Lin M.; Gut microbiota compositional profile and serum metabolic phenotype in patients with primary open-angle glaucoma. Exp Eye Res 2020,191,107921","journal-title":"Exp Eye Res"},{"key":"ref=115","doi-asserted-by":"publisher","first-page":"2738","DOI":"10.1038\/s41598-021-82538-0","volume":"11","author":"Das T.","year":"2021","unstructured":"Das T.; Jayasudha R.; Chakravarthy S.; Prashanthi G.S.; Bhargava A.; Tyagi M.; Rani P.K.; Pappuru R.R.; Sharma S.; Shivaji S.; Alterations in the gut bacterial microbiome in people with type 2 diabetes mellitus and diabetic retinopathy. Sci Rep 2021,11(1),2738","journal-title":"Sci Rep"},{"key":"ref=116","doi-asserted-by":"publisher","first-page":"E1677","DOI":"10.3390\/nu10111677","volume":"10","author":"Rinninella E.","year":"2018","unstructured":"Rinninella E.; Mele M.C.; Merendino N.; Cintoni M.; Anselmi G.; Caporossi A.; Gasbarrini A.; Minnella A.M.; The role of diet, micronutrients and the gut microbiota in age-related macular degeneration: New perspectives from the gut-retina axis. Nutrients 2018,10(11),E1677","journal-title":"Nutrients"},{"key":"ref=117","doi-asserted-by":"publisher","first-page":"535","DOI":"10.4103\/ijo.IJO_1362_20","volume":"69","author":"Shivaji S.","year":"2021","unstructured":"Shivaji S.; A systematic review of gut microbiome and ocular inflammatory diseases: Are they associated? Indian J Ophthalmol 2021,69(3),535-542","journal-title":"Indian J Ophthalmol"},{"key":"ref=118","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1126\/science.1219328","volume":"336","author":"Olszak T.","year":"2012","unstructured":"Olszak T.; An D.; Zeissig S.; Vera M.P.; Richter J.; Franke A.; Glickman J.N.; Siebert R.; Baron R.M.; Kasper D.L.; Blumberg R.S.; Microbial exposure during early life has persistent effects on natural killer T cell function. Science 2012,336(6080),489-493","journal-title":"Science"},{"key":"ref=119","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1167\/iovs.62.7.19","volume":"62","author":"Khan R.","year":"2021","unstructured":"Khan R.; Sharma A.; Ravikumar R.; Parekh A.; Srinivasan R.; George R.J.; Raman R.; Association between gut microbial abundance and sight-threatening diabetic retinopathy. Invest Ophthalmol Vis Sci 2021,62(7),19","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"ref=120","doi-asserted-by":"publisher","first-page":"e11128","DOI":"10.7717\/peerj.11128","volume":"9","author":"Shang J.","year":"2021","unstructured":"Shang J.; Liu F.; Zhang B.; Dong K.; Lu M.; Jiang R.; Xu Y.; Diao L.; Zhao J.; Tang H.; Liraglutide-induced structural modulation of the gut microbiota in patients with type 2 diabetes mellitus. PeerJ 2021,9,e11128","journal-title":"PeerJ"},{"key":"ref=121","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1111\/bph.13959","volume":"175","author":"Subramaniam S.","year":"2018","unstructured":"Subramaniam S.; Fletcher C.; Trimethylamine N-oxide: breathe new life. Br J Pharmacol 2018,175(8),1344-1353","journal-title":"Br J Pharmacol"},{"key":"ref=122","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1111\/obr.12843","volume":"20","author":"Zhuang R.","year":"2019","unstructured":"Zhuang R.; Ge X.; Han L.; Yu P.; Gong X.; Meng Q.; Zhang Y.; Fan H.; Zheng L.; Liu Z.; Zhou X.; Gut microbe-generated metabolite trimethylamine N-oxide and the risk of diabetes: A systematic review and dose-response meta-analysis. Obes Rev 2019,20(6),883-894","journal-title":"Obes Rev"},{"key":"ref=123","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1007\/s00592-020-01610-9","volume":"58","author":"Liu W.","year":"2021","unstructured":"Liu W.; Wang C.; Xia Y.; Xia W.; Liu G.; Ren C.; Gu Y.; Li X.; Lu P.; Elevated plasma trimethylamine-N-oxide levels are associated with diabetic retinopathy. Acta Diabetol 2021,58(2),221-229","journal-title":"Acta Diabetol"},{"key":"ref=124","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1136\/gutjnl-2018-316155","volume":"68","author":"Heianza Y.","year":"2019","unstructured":"Heianza Y.; Sun D.; Li X.; DiDonato J.A.; Bray G.A.; Sacks F.M.; Qi L.; Gut microbiota metabolites, amino acid metabolites and improvements in insulin sensitivity and glucose metabolism: The POUNDS Lost trial. Gut 2019,68(2),263-270","journal-title":"Gut"},{"key":"ref=125","doi-asserted-by":"publisher","first-page":"1512","DOI":"10.2337\/dc19-0048","volume":"42","author":"Winther S.A.","year":"2019","unstructured":"Winther S.A.; \u00d8llgaard J.C.; Tofte N.; Tarnow L.; Wang Z.; Ahluwalia T.S.; Jorsal A.; Theilade S.; Parving H.H.; Hansen T.W.; Hazen S.L.; Pedersen O.; Rossing P.; utility of plasma concentration of trimethylamine n-oxide in predicting cardiovascular and renal complications in individuals with Type 1 Diabetes. Diabetes Care 2019,42(8),1512-1520","journal-title":"Diabetes Care"}],"container-title":["Current Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0929867328666211129122908","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/198403\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0929867328666211129122908","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,9]],"date-time":"2023-08-09T16:02:04Z","timestamp":1691596924000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/198403\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":125,"journal-issue":{"issue":"40","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/0929867328666211129122908","relation":{},"ISSN":["0929-8673"],"issn-type":[{"value":"0929-8673","type":"print"}],"subject":[],"published":{"date-parts":[[2022,12]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2021-08-16","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-09-26","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-10-22","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-09-20","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}